Bailard, Inc. Intra Cellular Therapies, Inc. Call Options Transaction History
Bailard, Inc.
- $3.6 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding ITCI
# of Institutions
399Shares Held
87.1MCall Options Held
309KPut Options Held
302K-
Vanguard Group Inc Valley Forge, PA9.61MShares$700 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$461 Million0.01% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.72MShares$271 Million1.37% of portfolio
-
Jpmorgan Chase & CO New York, NY3.44MShares$250 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$219 Million2.8% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $6.88B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...